Dosing Begins in 3rd Phase 1 Study of AlzeCure’s ACD856

Dosing Begins in 3rd Phase 1 Study of AlzeCure’s ACD856

308448

Dosing Begins in 3rd Phase 1 Study of AlzeCure’s ACD856

The first patient has been dosed in a Phase 1 study that will test multiple ascending doses of ACD856, AlzeCure Pharma‘s lead therapeutic candidate for Alzheimer’s disease. According to a company press release, the trial — the third Phase 1 study testing the oral ACD856 experimental therapy — is proceeding according to plan, with results expected by June 2022. Its main goal is to evaluate the tolerability and safety of ACD856 after repetitive dosing, as…

You must be logged in to read/download the full post.